Advocacy at a Glance STEVEN GROSSMAN 11/3/23 Advocacy at a Glance STEVEN GROSSMAN 11/3/23 Senate Approves Agriculture/FDA Minibus Read More Analysis and Commentary STEVEN GROSSMAN 11/3/23 Analysis and Commentary STEVEN GROSSMAN 11/3/23 Level-Funding in FY 24: A Substantial Risk to FDA Priorities Read More Advocacy at a Glance STEVEN GROSSMAN 10/27/23 Advocacy at a Glance STEVEN GROSSMAN 10/27/23 Mike Johnson Elected as Speaker of the House - Further House Appropriations Action Proposed Read More Analysis and Commentary STEVEN GROSSMAN 10/27/23 Analysis and Commentary STEVEN GROSSMAN 10/27/23 Concrete Progress; Still A Long Way from Settling FDA’s FY 24 Funding Read More Advocacy at a Glance STEVEN GROSSMAN 10/23/23 Advocacy at a Glance STEVEN GROSSMAN 10/23/23 No Friday Update This Week - Quick Summary of the Ongoing Situation Read More Advocacy at a Glance STEVEN GROSSMAN 10/13/23 Advocacy at a Glance STEVEN GROSSMAN 10/13/23 Speaker Race in New Turmoil Read More Analysis and Commentary STEVEN GROSSMAN 10/13/23 Analysis and Commentary STEVEN GROSSMAN 10/13/23 FY 24 Appropriations: House Options Limited Regardless of Who Becomes Speaker Read More Advocacy at a Glance STEVEN GROSSMAN 10/6/23 Advocacy at a Glance STEVEN GROSSMAN 10/6/23 House Unlikely to Move Legislation Until New Speaker Selected Read More Analysis and Commentary STEVEN GROSSMAN 10/6/23 Analysis and Commentary STEVEN GROSSMAN 10/6/23 Lots to Learn from a Near-Shutdown Experience Read More Advocacy at a Glance STEVEN GROSSMAN 9/29/23 Advocacy at a Glance STEVEN GROSSMAN 9/29/23 Virtual Certainty of a Federal Government Shutdown on October 1 Despite Bipartisan Senate Effort Read More Analysis and Commentary STEVEN GROSSMAN 9/29/23 Analysis and Commentary STEVEN GROSSMAN 9/29/23 More Q&A As the Shutdown Becomes Inevitable Read More Advocacy at a Glance STEVEN GROSSMAN 9/22/23 Advocacy at a Glance STEVEN GROSSMAN 9/22/23 HHS Posts FY 2024 Contingency Staffing Plan, Including FDA Materials Read More Analysis and Commentary STEVEN GROSSMAN 9/22/23 Analysis and Commentary STEVEN GROSSMAN 9/22/23 Shutdown Becomes a Near-Certainty: Your Questions Answered Read More Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Prospects for Government Shutdown Increase Without Progress on Continuing Resolution Read More Analysis and Commentary STEVEN GROSSMAN 9/15/23 Analysis and Commentary STEVEN GROSSMAN 9/15/23 Q&A: Shutdowns at FDA Are Complicated Part 2 Read More Analysis and Commentary STEVEN GROSSMAN 9/8/23 Analysis and Commentary STEVEN GROSSMAN 9/8/23 Q&A: Shutdowns at FDA Are Complicated Read More Advocacy at a Glance STEVEN GROSSMAN 9/8/23 Advocacy at a Glance STEVEN GROSSMAN 9/8/23 How Likely Is a Shutdown? Read More Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Agriculture/FDA Appropriations: Unclear Picture of September Action Read More Analysis and Commentary STEVEN GROSSMAN 9/1/23 Analysis and Commentary STEVEN GROSSMAN 9/1/23 Product Shortages’ Prominent Place on FDA’s Agenda Read More Advocacy at a Glance STEVEN GROSSMAN 8/25/23 Advocacy at a Glance STEVEN GROSSMAN 8/25/23 Agriculture/FDA Appropriations Likely to be Overtaken by a Continuing Resolution Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 11/3/23 Advocacy at a Glance STEVEN GROSSMAN 11/3/23 Senate Approves Agriculture/FDA Minibus Read More
Analysis and Commentary STEVEN GROSSMAN 11/3/23 Analysis and Commentary STEVEN GROSSMAN 11/3/23 Level-Funding in FY 24: A Substantial Risk to FDA Priorities Read More
Advocacy at a Glance STEVEN GROSSMAN 10/27/23 Advocacy at a Glance STEVEN GROSSMAN 10/27/23 Mike Johnson Elected as Speaker of the House - Further House Appropriations Action Proposed Read More
Analysis and Commentary STEVEN GROSSMAN 10/27/23 Analysis and Commentary STEVEN GROSSMAN 10/27/23 Concrete Progress; Still A Long Way from Settling FDA’s FY 24 Funding Read More
Advocacy at a Glance STEVEN GROSSMAN 10/23/23 Advocacy at a Glance STEVEN GROSSMAN 10/23/23 No Friday Update This Week - Quick Summary of the Ongoing Situation Read More
Advocacy at a Glance STEVEN GROSSMAN 10/13/23 Advocacy at a Glance STEVEN GROSSMAN 10/13/23 Speaker Race in New Turmoil Read More
Analysis and Commentary STEVEN GROSSMAN 10/13/23 Analysis and Commentary STEVEN GROSSMAN 10/13/23 FY 24 Appropriations: House Options Limited Regardless of Who Becomes Speaker Read More
Advocacy at a Glance STEVEN GROSSMAN 10/6/23 Advocacy at a Glance STEVEN GROSSMAN 10/6/23 House Unlikely to Move Legislation Until New Speaker Selected Read More
Analysis and Commentary STEVEN GROSSMAN 10/6/23 Analysis and Commentary STEVEN GROSSMAN 10/6/23 Lots to Learn from a Near-Shutdown Experience Read More
Advocacy at a Glance STEVEN GROSSMAN 9/29/23 Advocacy at a Glance STEVEN GROSSMAN 9/29/23 Virtual Certainty of a Federal Government Shutdown on October 1 Despite Bipartisan Senate Effort Read More
Analysis and Commentary STEVEN GROSSMAN 9/29/23 Analysis and Commentary STEVEN GROSSMAN 9/29/23 More Q&A As the Shutdown Becomes Inevitable Read More
Advocacy at a Glance STEVEN GROSSMAN 9/22/23 Advocacy at a Glance STEVEN GROSSMAN 9/22/23 HHS Posts FY 2024 Contingency Staffing Plan, Including FDA Materials Read More
Analysis and Commentary STEVEN GROSSMAN 9/22/23 Analysis and Commentary STEVEN GROSSMAN 9/22/23 Shutdown Becomes a Near-Certainty: Your Questions Answered Read More
Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Advocacy at a Glance STEVEN GROSSMAN 9/15/23 Prospects for Government Shutdown Increase Without Progress on Continuing Resolution Read More
Analysis and Commentary STEVEN GROSSMAN 9/15/23 Analysis and Commentary STEVEN GROSSMAN 9/15/23 Q&A: Shutdowns at FDA Are Complicated Part 2 Read More
Analysis and Commentary STEVEN GROSSMAN 9/8/23 Analysis and Commentary STEVEN GROSSMAN 9/8/23 Q&A: Shutdowns at FDA Are Complicated Read More
Advocacy at a Glance STEVEN GROSSMAN 9/8/23 Advocacy at a Glance STEVEN GROSSMAN 9/8/23 How Likely Is a Shutdown? Read More
Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Advocacy at a Glance STEVEN GROSSMAN 9/1/23 Agriculture/FDA Appropriations: Unclear Picture of September Action Read More
Analysis and Commentary STEVEN GROSSMAN 9/1/23 Analysis and Commentary STEVEN GROSSMAN 9/1/23 Product Shortages’ Prominent Place on FDA’s Agenda Read More
Advocacy at a Glance STEVEN GROSSMAN 8/25/23 Advocacy at a Glance STEVEN GROSSMAN 8/25/23 Agriculture/FDA Appropriations Likely to be Overtaken by a Continuing Resolution Read More
